OncoMatch/Clinical Trials/NCT04974671
Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma
Is NCT04974671 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for renal cell carcinoma.
This Phase II trial will evaluate progression-free survival after Stereotactic Body Radiation Therapy to oligoprogressive (1-5) lesions in metastatic renal cell carcinoma patients on any immune checkpoint inhibitor-containing regimen with last dose of systemic therapy within 3 months prior to trial enrollment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: immune checkpoint inhibitor — most recent systemic therapy
The most recent systemic therapy must be an ICI-containing regimen, delivered for at least 3 months prior to development of oligoprogressive lesions, with the last dose received within 3 months of trial enrollment.
Cannot have received: radiation therapy
Has had radiation therapy within 2 weeks of the first protocol treatment.
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥ 1,500 /mcL; Platelets ≥ 75,000 / mcL; Hemoglobin ≥ 9 g/dL
Kidney function
Serum creatinine ≤1.5 X ULN OR measured/calculated creatinine clearance (GFR can also be used) ≥30 mL/min for subjects with creatinine > 1.5 X ULN
Liver function
Serum total bilirubin ≤ 1.5 X ULN; Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 ULN; AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN OR 5 X ULN for subjects with liver metastases
Demonstrate adequate organ function as defined in Table 4, all screening labs should be performed within 28 days of protocol treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Yale University · New Haven, Connecticut
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify